

Nathan Downie
Corporate Officer
Direct Line: 0151 643 5334
Email: foirequests.nhswirralccg@nhs.net

Date: 31st October 2017

Our Ref: ID 948



Wirral

Clinical Commissioning Group

NHS Wirral Clinical Commissioning Group
Old Market House
Hamilton Street
Birkenhead
Wirral
CH41 5AL
Tel: 0151 651 0011

Re: Freedom of Information Request

Thank you for your request for information made under the Freedom of Information Act 2000 which was received into this office on 5th October 2017.

You Asked for:

This letter is a freedom of information request made under the Freedom of Information Act 2000.

We request information in relation to the following medicines which are marketed for the treatment of chronic obstructive pulmonary disease:

- a) Anoro (vilanterol and umeclidinium) which is marketed by GlaxoSmithKline
- b) Braltus (tiotropium) which is marketed by Teva
- c) Duaklir (aclidinium bromide and formoterol fumarate dihydrate) which is marketed by Astra Zeneca
- d) Eklira (aclidinium) which is marketed by Astra Zeneca
- e) Incruse (umeclidinium) which is marketed by GlaxoSmithKline
- f) Seebri (glycopyrronium) which is marketed by Novartis
- g) Spiolto (tiotropium and olodaterol) which is marketed by Boehringer Ingelheim
- h) Spiriva (tiotropium) which is marketed by Boehringer Ingelheim
- i) Trimbow (formoterol fumarate dihydrate, beclometasone dipropionate and glycopyrronium (as bromide) which is marketed by Chiesi
- j) Ultibro (indacaterol and glycopyrronium) which is marketed by Novartis or Pfizer

(the “**COPD Medicines**”).

In respect of each of the COPD Medicines, please could you provide us with the following information:

- 1) A copy of any agreement relating to a rebate, discount, patient access, risk-sharing or other pricing scheme entered into by NHS Wirral CCG in relation to the COPD Medicines which results in NHS Wirral CCG paying less than the NHS list price for such COPD Medicines (whether by way of discount, rebate etc).
- 2) A copy of any communications between NHS Wirral CCG and the company or companies marketing such COPD Medicine in relation to such scheme
- 3) Any information or requests sent to GP practices comprised within the CCG in the 6 months since contract signature with respect to such COPD Medicines schemes

Our Response:

1. The pharmaceutical companies disclosure is not permitted, as this falls under the section 43 (2) exemption of the Freedom of Information Act (FOI) 2000.
2. There is only piece of correspondence between the CCG and Boehringer Ingelheim Ltd which includes commercially sensitive information. Therefore, this information is considered exempt under section 43 (2) of the Freedom of Information Act (FOI) 2000.
3. There have been no information or requests sent to GP practices comprised within the CCG in the 6 months since contract signature with respect to such COPD Medicines schemes

We hope this information is useful, however if you require any further information please do not hesitate to contact a member of the Corporate Affairs Team (contact details at the top of this letter)

Re- Use of Information

Most of the information that we provide in response to Freedom of Information Act 2000 requests will be subject to copyright protection. In most cases the copyright will be owned by Wirral Clinical Commissioning Group. The copyright in other information may be owned by another person or organisation, as indicated on the information itself.

You are free to use any information supplied for your own non-commercial research or private study purposes. The information may also be used for any other purpose allowed by a limitation or exception in copyright law, such as news reporting. However, any other type of re-use, for example by publishing the information in analogue or digital form, including on the internet, will require the permission of the copyright owner.

For information where the copyright is owned by Wirral Clinical Commissioning Group please e-mail foirequests.nhsWirralccg@nhs.net to request a reuse licence.

For information where the copyright is owned by another person or organisation you must apply to the copyright owner to obtain their permission.